The compound PMD-026 is the first RSK inhibitor undergoing clinical trial in the US in patients with metastatic and triple-negative breast cancer, and the trial is currently ongoing (NCT04115306). Here, RPS6KA1 is linked to triple-negative breast carcinoma.